Physician profile
Keli E Hall
NPI 1699215079
$1,069.37
in general payments reported to CMS, 2019-2025
10 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $222 · 2023: $275 · 2024: $170 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.16 |
| Education | $216.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $388.81 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $230.03 | 2021-2025 | |
| Abbvie INC. | $161.48 | 2021-2025 | |
| Amgen INC. | $140.55 | 2021-2023 | Otezla |
| Lilly USA, LLC | $65.66 | 2024-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $17.76 | 2022 | |
| Dermavant Sciences, INC. | $17.66 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $17.40 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.42 | 2025 | Sotyktu |
| Ucb, INC. | $13.60 | 2024 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keli Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.